金凯生科(301509)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301509 金凯生科

已收盘 02-06 15:00:00

{"stockData":{"symbol":"301509","market":"SZ","secType":"STK","nameCN":"金凯生科","latestPrice":39.37,"timestamp":1770361404000,"preClose":38.48,"halted":0,"volume":10583880,"delay":0,"changeRate":0.0231,"floatShares":56740900,"shares":120000000,"eps":0.8531,"marketStatus":"已收盘","change":0.89,"latestTime":"02-06 15:00:00","open":38.6,"high":40.44,"low":37.6,"amount":416000000,"amplitude":0.0738,"askPrice":39.38,"askSize":11,"bidPrice":39.37,"bidSize":8,"shortable":0,"etf":0,"ttmEps":0.8531,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":38.48,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":42.33,"lowLimit":34.63,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":120446669,"isCdr":false,"pbRate":2.1,"roa":"--","peRate":46.149338,"roe":"4.74%","epsLYR":0.32,"committee":-0.114894,"marketValue":4742000000,"turnoverRate":0.1865,"status":0,"floatMarketCap":2234000000},"requestUrl":"/m/hq/s/301509","defaultTab":"news","newsList":[{"id":"2609432019","title":"2月5日金凯生科现202.35万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2609432019","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609432019?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:27","pubTimestamp":1770283628,"startTime":"0","endTime":"0","summary":"证券之星消息，2月5日金凯生科发生大宗交易，交易数据如下：大宗交易成交价格35.5元，相对当日收盘价折价7.74%，成交5.7万股，成交金额202.35万元，买方营业部为国投证券股份有限公司河源分公司，卖方营业部为中国中金财富证券有限公司北京建国门外大街证券营业部。近三个月该股共发生11笔大宗交易，合计成交9290.0手，折价成交11笔。截至2026年2月5日收盘，金凯生科报收于38.48元，上涨5.89%，换手率18.11%，成交量10.28万手，成交额4.01亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500027975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"2607091073","title":"金凯生科：公司储备的临床期项目涉及肿瘤、免疫等多个疾病治疗领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2607091073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607091073?lang=zh_cn&edition=full","pubTime":"2026-01-30 15:27","pubTimestamp":1769758033,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)01月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董，你好。你们带电棒的时候说你们手握几个临床资源。请问你们这个说的临床资源是包含哪些疾病的？最新进展如何？金凯生科回复：尊敬的投资者，您好！公司储备的临床期项目涉及肿瘤、免疫等多个疾病治疗领域，公司会严格按照信息披露规则披露项目信息。由于临床期项目到获批上市仍具有较大不确定性，所以请您关注相关投资风险。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000020472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"gpt_icon":0},{"id":"2606883265","title":"股市必读：金凯生科（301509）预计2025年全年扣非后净利润盈利7200万元至9100万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606883265","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606883265?lang=zh_cn&edition=full","pubTime":"2026-01-26 02:45","pubTimestamp":1769366712,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，金凯生科报收于38.92元，上涨0.0%，换手率6.17%，成交量3.5万手，成交额1.36亿元。来自：金凯生科预计2025年度归属净利润同比增长138.28%至200.45%，主要受益于终端需求回暖与毛利率提升。金凯生科发布业绩预告，预计2025年全年归属净利润盈利9200万元至1.16亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509"],"gpt_icon":0},{"id":"2605547574","title":"金凯生科最新公告：2025年净利同比预增138.28%-200.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605547574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605547574?lang=zh_cn&edition=full","pubTime":"2026-01-23 17:50","pubTimestamp":1769161822,"startTime":"0","endTime":"0","summary":"金凯生科(301509.SZ)发布2025年度业绩预告，预计归属于上市公司股东的净利润为9200万元–1.16亿元，比上年同期增长138.28%–200.45%。受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加；同时受交付订单产品结构影响，公司总体毛利率有所提高。以上综合因素导致公司2025年度业绩同比出现较大幅度提升。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300029929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"2605487824","title":"股市必读：金凯生科（301509）1月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605487824","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605487824?lang=zh_cn&edition=full","pubTime":"2026-01-22 02:46","pubTimestamp":1769021170,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，金凯生科报收于39.32元，上涨0.36%，换手率10.17%，成交量5.77万手，成交额2.27亿元。董秘最新回复投资者： 董秘您好，请问贵公司生产的医药中间体有没有应用在替尔泊肽上！您提到的相关产品获批上市的均为注射剂型，公司没有产品应用到相关注射剂领域。截至2026年1月20日，公司股东数为14,722户。当日关注点来自交易信息汇总：1月21日主力资金净流出398.15万元，游资资金净流出1086.75万元，散户资金净流入1484.91万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200001088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"gpt_icon":0},{"id":"2605172093","title":"金凯生科：截至2026年1月20日股东数为14,722户","url":"https://stock-news.laohu8.com/highlight/detail?id=2605172093","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605172093?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:06","pubTimestamp":1768986377,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司截止到一月二十日股东人数是多少？金凯生科回复：尊敬的投资者，您好！截至2026年1月20日，公司股东数为14,722户。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100027798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"2603022495","title":"金凯生科(301509)1月9日股东户数1.45万户，较上期增加2.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603022495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603022495?lang=zh_cn&edition=full","pubTime":"2026-01-13 17:42","pubTimestamp":1768297360,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金凯生科披露，截至2026年1月9日公司股东户数为1.45万户，较12月31日增加406.0户，增幅为2.87%。在医疗服务行业个股中，金凯生科股东户数低于行业平均水平，截至1月9日，医疗服务行业平均股东户数为4.5万户。从股价来看，2025年12月31日至2026年1月9日，金凯生科区间涨幅为6.6%，在此期间股东户数增加406.0户，增幅为2.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300029995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"2603503052","title":"金凯生科：公司没有涉及相关领域的产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2603503052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603503052?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:27","pubTimestamp":1768289241,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)01月13日在投资者关系平台上答复投资者关心的问题。投资者提问：马斯克近期声称人类可以实现半永生，主要指通过干预细胞层面的代码延缓衰老与死亡。请问贵司的小分子药物有可能实现类似作用与功效吗？金凯生科回复：尊敬的投资者，您好！公司没有涉及相关领域的产品。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300020143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"2601519318","title":"金凯生科：截至2025年12月31日股东数为14,132户","url":"https://stock-news.laohu8.com/highlight/detail?id=2601519318","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601519318?lang=zh_cn&edition=full","pubTime":"2026-01-06 09:18","pubTimestamp":1767662293,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止12月31日公司股东人数是多少？金凯生科回复：尊敬的投资者，您好！截至2025年12月31日，公司股东数为14,132户。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600007678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"2594260713","title":"12月26日金凯生科现10笔大宗交易 机构净买入431.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594260713","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594260713?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:43","pubTimestamp":1766742217,"startTime":"0","endTime":"0","summary":"证券之星消息，12月26日金凯生科发生大宗交易，交易数据如下：近三个月该股共发生10笔大宗交易，合计成交8720.0手，折价成交10笔。该股近期无解禁股上市。截至2025年12月26日收盘，金凯生科(301509)报收于34.21元，下跌1.89%，换手率3.05%，成交量1.73万手，成交额5946.74万元。该股近半年内有股东持股变动，合计净减持531.26万股，股东增减持明细如下表：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600025616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"2594628592","title":"金凯生科：合理规划产能确保重点项目需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2594628592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594628592?lang=zh_cn&edition=full","pubTime":"2025-12-26 15:51","pubTimestamp":1766735469,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)12月26日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好。诺和诺德司美格鲁肽口服减肥药已在美获批，snac中间体需求量暴增，公司有足够产量硬怼吗？金凯生科回复：尊敬的投资者，您好！公司会结合市场信息与客户需求指引，合理规划准备产能、科学优化安排生产，确保重点项目的产能需求。有关公司业务的具体信息，请以公司信息披露公告为准。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600017268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"2593277444","title":"金凯生科：严格规范的质量管理贯穿研发生产到交付","url":"https://stock-news.laohu8.com/highlight/detail?id=2593277444","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593277444?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:54","pubTimestamp":1766562859,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科12月24日在投资者关系平台上答复投资者关心的问题。公司医药领域的产品主要为医药中间体及原料药，严格规范的质量管理始终贯穿于产品研发、生产到交付的整个服务周期。公司国内生产基地建立了 ISO 管理体系并持续获得认证通过，公司美国生产基地建立了 cGMP 体系并获得美国、日本的药品监督管理机构现场检查通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400020249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"gpt_icon":0},{"id":"2593688107","title":"金凯生科：截至2025年12月19日股东数为14,278户","url":"https://stock-news.laohu8.com/highlight/detail?id=2593688107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593688107?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:54","pubTimestamp":1766390069,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至12月20日公司的股东人数是多少？谢谢金凯生科回复：尊敬的投资者，您好！截至2025年12月19日，公司股东数为14,278户。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200013465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"gpt_icon":0},{"id":"2591615351","title":"金凯生科：截至2025年12月10日股东数为14,355户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591615351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591615351?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:31","pubTimestamp":1765783860,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月10日股东人数是多少？金凯生科回复：尊敬的投资者，您好！截至2025年12月10日，公司股东数为14,355户。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"2588747788","title":"金凯生科：截至2025年11月28日股东数为14,539户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588747788","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588747788?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:21","pubTimestamp":1764577272,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至11月30日的股东人数是多少？谢谢金凯生科回复：尊敬的投资者，您好！截至2025年11月28日，公司股东数为14,539户。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100016265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"2585970271","title":"金凯生科：截至2025年11月20日股东数为14,972户","url":"https://stock-news.laohu8.com/highlight/detail?id=2585970271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585970271?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:48","pubTimestamp":1763711294,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)11月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，你好!请问截止至2025年11月20日，公司股东人数总数是多少?谢谢!金凯生科回复：尊敬的投资者，您好！截至2025年11月20日，公司股东数为14,972户。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100018781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"gpt_icon":0},{"id":"2585197786","title":"金凯生科：主要设备及材料均为国产","url":"https://stock-news.laohu8.com/highlight/detail?id=2585197786","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585197786?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:39","pubTimestamp":1763710749,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)11月21日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司在生产研发过程中，是否有关键材料或设备需要从日本进口？若两国关系突然紧张无法获得相关材料，是否会对贵司生产研发造成卡脖子风险？金凯生科回复：尊敬的投资者，您好！公司主要研发与生产设备及生产使用的主要原辅材料均为国产，不存在您提到的相关风险。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100018523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"gpt_icon":0},{"id":"2584482129","title":"金凯生科最新公告：股东启鹭投资、青松投资、蓝区基金拟合计减持不超5.94%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2584482129","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584482129?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:20","pubTimestamp":1763551247,"startTime":"0","endTime":"0","summary":"金凯生科公告称，股东启鹭投资计划减持不超过361.20万股，其中集中竞价减持不超过120.40万股，大宗交易减持不超过240.80万股；青松投资计划通过集中竞价减持不超过120.40万股；蓝区基金计划减持不超过233.91万股，其中集中竞价减持不超过120.40万股，大宗交易减持不超过113.51万股。减持原因均为自身资金需求。集中竞价减持期间为公告披露之日起十五个交易日后的三个月内，大宗交易减持期间为公告披露之日起三个交易日后的三个月内。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900033829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"gpt_icon":0},{"id":"1114057291","title":"金凯生科股东计划在三个月内减持最多5.9%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1114057291","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114057291?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:16","pubTimestamp":1763550987,"startTime":"0","endTime":"0","summary":"金凯生科表示，股东计划在未来三个月内减持最多5.9%的股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301509","BK0239"],"gpt_icon":0},{"id":"2582311176","title":"金凯生科：截至2025年11月10日股东数为14,577户","url":"https://stock-news.laohu8.com/highlight/detail?id=2582311176","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582311176?lang=zh_cn&edition=full","pubTime":"2025-11-12 08:54","pubTimestamp":1762908855,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)11月11日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，请问截止到11月10日，公司股东人数有多少？金凯生科回复：尊敬的投资者，您好！截至2025年11月10日，公司股东数为14,577户。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200005858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770527711722,"stockEarnings":[{"period":"1week","weight":0.0834},{"period":"1month","weight":0.1239},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0245},{"period":"1year","weight":0.5752},{"period":"ytd","weight":0.1655}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"金凯(辽宁)生命科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14722人(较上一季度增加1.27%)","perCapita":"3854股","listingDate":"2023-08-03","address":"辽宁省阜新市阜新蒙古族自治县伊吗图镇氟化工园区安仁路6号","registeredCapital":"12044万元","survey":"　　金凯(辽宁)生命科技股份有限公司的主营业务是为全球原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定制研发生产服务。公司的主要产品是三氟甲氧基或三氟甲基的苯类中间体、氟代芳环类中间体、含氮杂环系列、氨的脂肪族有机衍生物、羧酸及其衍生物、烯烃类、非氟卤代苯类、酚类、酮类、异氰酸酯类。","listedPrice":56.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金凯生科(301509)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金凯生科(301509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金凯生科,301509,金凯生科股票,金凯生科股票老虎,金凯生科股票老虎国际,金凯生科行情,金凯生科股票行情,金凯生科股价,金凯生科股市,金凯生科股票价格,金凯生科股票交易,金凯生科股票购买,金凯生科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金凯生科(301509)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金凯生科(301509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}